What is it about?
Surgical treatment is the mainstay of treatment strategy for locally advanced head and neck cancer. And post operative chemoradiotherapy for the patients with high-risk features can improve treatment outcomes. However, the standard treatment of 3-weekly cisplatin with 100 mg/m2 plus RT is not necessarily feasible treatment for these patients. Thus, we conducted a randomized phase II/III trial to prove non-inferiority of weekly cisplatin plus RT comparing with 3-weekly cisplatin plus RT in terms of overall survival.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
The result provides evidence that weekly cisplatin plus RT can be a new standard treatment option for patients with postoperative high-risk LA-SCCHN.
Perspectives
Weekly cisplatin plus RT can provide equal efficacy and better safety for the post-operative high-risk HNSCC patients. This treatment may fit for the frail or elderly patients who are intolerable to high-dose cisplatin.
Naomi Kiyota
Kobe University Hospital
Read the Original
This page is a summary of: Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial, Journal of Clinical Oncology, March 2022, American Society of Clinical Oncology (ASCO),
DOI: 10.1200/jco.21.01293.
You can read the full text:
Resources
Research gate
You can DL from this link, too
Research at Kobe
Press release in Japanese.
Research map
You can find my publications from this site, too.
Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial
Journal of Clinical Oncology, open access
Contributors
The following have contributed to this page
